8-K: QuidelOrtho Reports Q1 2026 Results, Updates Guidance

QuidelOrtho announced first quarter 2026 financial results, reporting $620 million in total revenue, and updated its full-year 2026 financial guidance.

Summary

• QuidelOrtho reported total revenues of $619.8 million for the first quarter ended March 29, 2026, a decrease of 10.5% compared to the prior year period.
• Point of Care revenue declined 34% to $113 million, attributed to a weaker respiratory season.
• Labs revenue decreased 5% to $353 million, impacted by slower sales in China and business disruption in the Middle East.
• Immunohematology revenue grew 8% to $138 million, driven by North America, China, and JPAC.
• The company reported a GAAP net loss of $91.8 million and an adjusted EBITDA of $108.7 million.
• Full-year 2026 revenue guidance was updated to $2.70 - $2.75 billion, down from $2.7 - $2.9 billion.
• Adjusted EBITDA guidance for the full year was revised to $615 - $630 million, from $630 - $670 million.
• The acquisition of LEX Diagnostics was completed in April 2026, adding a molecular diagnostics platform.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue declines in key segments, a widened net loss, and reduced full-year financial guidance, despite strategic acquisitions and product launches.

Positives

• Immunohematology revenue grew 8% as reported and 3% in constant currency, driven by growth in North America, China and JPAC.
• The acquisition of LEX Diagnostics is expected to accelerate growth in point-of-care molecular diagnostics.
• Key product launches, including the High-Sensitivity Troponin assay and the VITROS 450 platform, are expected to drive future growth.
• Management believes the underlying business remains strong and is well-positioned to expand adjusted EBITDA margin and improve cash flow in 2026.

Negatives

• Total revenues decreased by 10.5% to $619.8 million in Q1 2026 compared to the prior year.
• Point of Care revenue declined significantly by 34% to $113 million due to a weaker respiratory season.
• Labs revenue decreased by 5% to $353 million, impacted by distributor sales in China and Middle East conflict.
• GAAP net loss for the quarter was $91.8 million, compared to a net loss of $12.7 million in the prior year.
• Adjusted EBITDA decreased to $108.7 million from $159.8 million in the prior year.
• Full-year 2026 revenue guidance has been lowered to $2.70 - $2.75 billion from $2.7 - $2.9 billion.
• Full-year 2026 adjusted EBITDA guidance has been reduced to $615 - $630 million from $630 - $670 million.
• Free cash flow guidance for the full year has been reduced to $100 - $120 million from $120 - $160 million.

Risks

• Pending changes to China National Health Security Administration (NHSA) In Vitro Diagnostics (IVD) pricing guidelines may impact Labs revenue.
• Business disruption related to the Middle East conflict could affect revenue.
• The Company cannot fully assess the impact of the current draft of China NHSA IVD pricing guidelines until final guidelines and implementation timelines are confirmed.
• Guidance does not assume a significant, prolonged impact related to the Middle East conflict.
• Fluctuations in demand for non-respiratory and respiratory products.
• Supply chain, production, logistics, distribution, and labor disruptions and challenges.
• Delays in the development of or failures or delays in the receipt of approvals for new or enhanced products.
• Changes in reimbursement rates for products, including proposed reductions by China NHSA.

Future Outlook

The company has updated its full-year 2026 financial guidance, now projecting total revenues between $2.70 - $2.75 billion, adjusted EBITDA between $615 - $630 million, adjusted diluted earnings per share between $1.80 - $2.00, and free cash flow between $100 - $120 million. This updated guidance considers the first-quarter performance and current market dynamics in China, including expected impacts from draft China NHSA IVD pricing guidelines.

Management Comments

• "Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East."
• "Importantly, we believe the underlying business remains strong and we are well positioned to deliver on our objectives to expand our adjusted EBITDA margin and improve cash flow in 2026."
• "We completed our acquisition of LEX Diagnostics in April, adding an ultra-fast molecular diagnostics platform for point-of-care testing. We also advanced our key strategic priorities, including the U.S. launch of our High-Sensitivity Troponin assay and the rollout of the VITROS 450 platform in select international markets. We believe these innovations enhance our portfolio and position us to drive sustainable, long-term growth."

Industry Context

StockSavvy.ai notes that QuidelOrtho's Q1 2026 results reflect challenges common in the diagnostics sector, including seasonal demand fluctuations (respiratory season) and geopolitical impacts (Middle East conflict) affecting supply chains and sales. The company's strategic focus on molecular diagnostics via the LEX acquisition and new product launches aligns with industry trends towards more advanced point-of-care testing.

Comparison to Industry Standards

• The 34% decline in Point of Care revenue due to a weaker respiratory season is a significant deviation from typical seasonal patterns seen in diagnostic companies reliant on such cycles.
• The 5% decline in Labs revenue, attributed partly to China's regulatory environment and geopolitical issues, mirrors concerns faced by other global healthcare companies operating in or selling into China.
• The 8% growth in Immunohematology revenue demonstrates resilience in a specific segment, potentially outperforming broader market trends for less specialized diagnostic areas.

Stakeholder Impact

• Shareholders: Negative impact due to reduced financial guidance and current quarter performance, potentially affecting stock price.
• Employees: Potential impact on morale and future compensation due to financial performance and strategic shifts.
• Customers: May experience continued disruption in China due to pricing guideline changes and Middle East conflict impacts on supply.
• Suppliers: Potential for adjusted order volumes based on revised revenue forecasts.

Next Steps

• Hold an earnings conference call on May 5, 2026, to discuss Q1 2026 results.
• Continue to monitor and assess the impact of China NHSA IVD pricing guidelines.
• Integrate the LEX Diagnostics acquisition to accelerate growth.
• Drive sustainable, long-term growth through product innovations like the High-Sensitivity Troponin assay and VITROS 450 platform.

Key Dates

Recommendation

While the Q1 results and updated guidance are negative, the company's strategic acquisition of LEX Diagnostics and ongoing product development show potential for future recovery. The current 'hold' recommendation balances the short-term headwinds with the long-term strategic initiatives and market position in diagnostics.

Keywords

QuidelOrtho, QDEL, Financial Results, First Quarter, Diagnostics, Revenue, EBITDA, Guidance Update